Expression of prostate-specific membrane antigen in renal cortical tumors
Expression of prostate-specific membrane antigen in renal cortical tumors
复制标题
DOI：
10.1038/modpathol.2008.42
复制
发表时间：
2008-06-01
期刊：
影响因子：
7.5
通讯作者：
Reuter, Victor E.
中科院分区：
文献类型：
--
作者：
Al-Ahmadie, Hikmat A.;Olgac, Semra;Reuter, Victor E.
前列腺特异性膜抗原是一种II型膜糖蛋白，其在良性和肿瘤性前列腺组织中表达，并且最近已显示也在各种实体恶性肿瘤（包括肾细胞癌）的新血管中表达。肾细胞癌是一组异质性肿瘤，具有不同的形态学、遗传学特征和临床表现。我们进行了福尔马林固定，石蜡包埋的档案材料75肾切除术，使用抗体13 D 6对前列腺特异性膜抗原和CD 31对内皮细胞的免疫组化研究。该研究包括30例透明细胞肾细胞癌，乳头状和嫌色细胞肾细胞癌和嗜酸细胞瘤各15例。染色的程度和强度进行了半定量评估。在所有情况下，免疫反应性仅在肿瘤相关的新生血管中检测到，而在肿瘤细胞中未检测到。透明细胞肾细胞癌显示最弥漫的染色模式，其中24/30例或80%有450%的反应性血管，其次是嫌色细胞肾细胞癌（9/15; 60%）和嗜酸细胞瘤（5/15，33%）。所有乳头状肾细胞癌均未检测到弥漫性染色，11例（11/15; 73%）仅检测到局灶性染色。染色强度在肾透明细胞癌中最强（25/30; 83%），其次是肾嫌色细胞癌（9/15; 60%）、嗜酸细胞瘤（8/15; 53%）和乳头状肾细胞癌（5/15; 33%）。总之，前列腺特异性膜抗原在大多数肾皮质肿瘤的肿瘤相关新生血管中表达，并且在透明细胞肾细胞癌中表达最广泛和强烈，在乳头状肾细胞癌中表达最少。肾细胞癌亚型中前列腺特异性膜抗原表达的差异提供了这些肿瘤生物多样性的进一步证据，并且这种表达的诊断和治疗应用可以扩展到包括肾细胞癌亚型。
Prostate-specific membrane antigen is a type II membrane glycoprotein that is expressed in benign and neoplastic prostatic tissue and has been recently shown to be also expressed in the neovasculature of various solid malignant tumors including renal cell carcinoma. Renal cell carcinoma is a heterogeneous group of tumors with distinct morphologic and genetic characteristics and clinical behaviors. We performed immunohistochemical studies on formalin-fixed, paraffin-embedded archival material from 75 nephrectomies, using antibodies 13D6 against prostate-specific membrane antigen and CD31 against endothelial cells. The study included 30 clear cell renal cell carcinomas, and 15 of each of papillary and chromophobe renal cell carcinoma and oncocytoma. The extent and intensity of staining were assessed semiquantitatively. In all cases, immunoreactivity was detected only in the tumor-associated neovasculature and not in tumor cells. Clear cell renal cell carcinoma showed the most diffuse staining pattern, where 24/30 cases or 80% had 450% reactive vessels, followed by chromophobe renal cell carcinoma (9/15; 60%) and oncocytoma (5/15, 33%). No diffuse staining was detected in any of the papillary renal cell carcinomas and only focal staining was detected in 11 cases (11/15; 73%). Staining intensity was the strongest in clear cell renal cell carcinoma (25/30; 83%) followed by chromophobe renal cell carcinoma (9/15; 60%), oncocytoma (8/15, 53%) and papillary renal cell carcinoma (5/15; 33%). In summary, prostate-specific membrane antigen is expressed in tumor-associated neovasculature of the majority of renal cortical tumors and is most diffusely and intensely expressed in clear cell renal cell carcinoma and least in papillary renal cell carcinoma. The differences in the expression of prostate-specific membrane antigen in renal cell carcinoma subtypes provide further evidence of the biological diversity of these tumors, and diagnostic and therapeutic applications of such expression can be expanded to include subtypes of renal cell carcinoma.